Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean ...

Fulcrum Therapeutics used its presentation at ASH for its sickle cell disease drug as a springboard for raising US$175m from a one-day marketed follow-on, a more modest (than Terns) 16.7% upsize from ...

Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week 6 ...

Piper Sandler boosted its target price to $23 per share from $16. ・Wainwright increased its price target to $25 from $18, ...

Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the presentation of new preclinical data on ...

Researchers at the University of Cincinnati presented findings on treatments for blood cancers at a hematology event.

Adding erythropoietin to hydroxyurea treatment could significantly improve quality of life for patients with sickle cell ...

The $10 billion Nigeria LNG Limited Train-7 gas project, is progressively advancing towards completion phase as contractors ...

ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute ...

Investing.com -- Fulcrum Therapeutics (NASDAQ:FULC) stock surged 50% Monday after the company reported positive initial results from its Phase 1b PIONEER trial of pociredir in sickle cell disease ...

Research shows that ultra-processed foods are bad for health, but which ones are the worst? If you're trying to cut back, ...